dc.contributorCosta, Juvenal Soares Dias da
dc.creatorGaedke, Mari Ângela
dc.date.accessioned2015-07-06T22:12:30Z
dc.date.accessioned2022-09-09T21:30:18Z
dc.date.accessioned2023-03-13T19:07:56Z
dc.date.available2015-07-06T22:12:30Z
dc.date.available2022-09-09T21:30:18Z
dc.date.available2023-03-13T19:07:56Z
dc.date.created2015-07-06T22:12:30Z
dc.date.created2022-09-09T21:30:18Z
dc.date.issued2013
dc.identifierhttp://148.201.128.228:8080/xmlui/handle/20.500.12032/32497
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6147671
dc.description.abstractWe verify the prevalence of medication recommended in secondary prevention of Acute Coronary Syndrome in patient discharge and follow-up of a six months and one year period. We used data from a cohort study which included patients 30 years old or older, of both genders, discharged of hospital in southern Brazil. The outcome was the simultaneous use of drugs recommended by scientific evidence for secondary prevention: antiplatelet agents, beta-blocker, statin and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; and use of dual antiplatelet blockage. Among the 138 people included, 36.2% were prescribed the four drugs at discharge, and 64,5% and dual blockage. In the analysis there was no association between exposure and the use of the four drugs. Regarding the use of antiplatelet blockage there was a decrease in the follow-up, but he was more frequent in subjects who underwent percutaneous coronary intervention. The prevalence of drug use at discharge and follow-up showed underutilization of this therapy in clinical practice.
dc.publisherUniversidade do Vale do Rio dos Sinos
dc.rightsopenAccess
dc.subjectSíndrome Coronariana Aguda
dc.subjectAcute Coronary Syndrome
dc.titleUso de medicamentos recomendados na prevenção secundária da Síndrome Coronariana Aguda
dc.typeDissertação


Este ítem pertenece a la siguiente institución